[A18-85] Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 06.06.2019
Project no.:
A18-85
Commission:
Commission awarded on 11.12.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Hepatocellular carcinoma after prior sorafenib therapy
Advantage in overall survival, negative effects in severe/serious side effects; overall indication of minor added benefit versus best supportive care
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2019-06-06 A G-BA decision was published.